Xcout Intel
Vella Bioscience, Inc.
Vella Bioscience, Inc. is a United States-based company specializing in women's intimate care, arousal, and wellness products. Its offerings are designed to enhance arousal, comfort, and hormonal balance.
Subscribe to see Vella Bioscience, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Vella Bioscience, Inc. at a glance
Vella Bioscience, Inc. is a biotechnology company headquartered in United States. Its most recent funding round, Seed II, raised $4M in July 2026. Xcout tracks 1 named person at Vella Bioscience, Inc., including Harin Padma-Nathan (Chief Medical Officer).
Vella Bioscience, Inc. leadership
- Harin Padma-NathanChief Medical Officer
Vella Bioscience, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed II | $4M | 1 named | |
| Seed | $7M | 2 named | |
| SEC Form D filing | $1.6M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Vella Bioscience, Inc. competitors
A few of Vella Bioscience, Inc.'s closest competitors — see the full list of competitors and alternatives →
Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is Phexxi, a vaginal gel specifically designed as a contraceptive. Additionally, the company is actively advancing EVO100, an antimicrobial vaginal gel under development, intended to prevent the urogenital spread of both Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. The company's main office is situated in San Diego, California.
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.
MenoGeniX, Inc. is a pharmaceutical and healthcare company headquartered in Colorado, United States. The company focuses on the development of therapeutic products targeting women's health.
Zero Candida Technologies, Inc. is a publicly traded FemTech company that designs, develops, manufactures, and sells non-drug blue light therapy devices for women's health. The company is developing an AI-driven, smart tampon-like medical device utilizing a therapeutic light source to address unmet needs in gynecology.
Oriva Therapeutics is a biotechnology and pharmaceutical company headquartered in Barcelona, Spain. The venture is dedicated to advancing innovative and disease-modifying approaches to improve clinical outcomes for chronic women's health conditions.
Hera Diagnostics Corp develops non-invasive, AI-powered diagnostic tools and molecular tests for women's health conditions, focusing on endometriosis detection and staging as well as point-of-care cervical cancer screening. The company provides practice-ready diagnostic solutions for OB-GYN, fertility, and clinical care workflows.
Get Vella Bioscience, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Vella Bioscience, Inc. in Xcout Intel
- 1 named person with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access